Characterizations of Human UDP-Glucuronosyltransferase Enzymes in the Conjugation of p-Cresol
Abstract p-Cresol is a uremic toxin that is formed by intestinal microbiota and extensively conjugated by first-pass metabolism. p-Cresol glucuronide exerts various forms of cellular toxicity in vitro and is accumulated in the plasma of subjects with kidney disease, where associations with adverse c...
Saved in:
| Published in | Toxicological sciences Vol. 176; no. 2; pp. 285 - 296 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Oxford University Press
01.08.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1096-6080 1096-0929 1096-0929 |
| DOI | 10.1093/toxsci/kfaa072 |
Cover
| Abstract | Abstract
p-Cresol is a uremic toxin that is formed by intestinal microbiota and extensively conjugated by first-pass metabolism. p-Cresol glucuronide exerts various forms of cellular toxicity in vitro and is accumulated in the plasma of subjects with kidney disease, where associations with adverse cardiovascular and renal outcomes are evident. The objective of this study was to determine the contributions of human UDP-glucuronosyltransferase (UGT) enzymes in the formation of p-cresol glucuronide. Utilizing commonly expressed hepatic or renal human recombinant UGTs (ie, hrUGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, and 2B17), hrUGT1A6 and hrUGT1A9 exhibited the highest catalytic activities in the generation of p-cresol glucuronide. The kinetics of p-cresol glucuronide formation in hrUGT1A6 and pooled human liver microsomes were best described by the Hill equation and in hrUGT1A9 and pooled human kidney microsomes by substrate inhibition. Using inhibitory and selective UGT inhibitors (ie, acetaminophen or amentoflavone for UGT1A6 and niflumic acid for UGT1A9), UGT1A6 was identified the predominant enzyme responsible for p-cresol glucuronide production in pooled human liver (78.4%–81.3% contribution) and kidney (54.3%–62.9%) microsomes, whereas UGT1A9 provided minor contributions (2.8% and 35.5%, respectively). The relative contributions of UGT1A6 (72.6 ± 11.3%, mean ± SD) and UGT1A9 (5.7 ± 4.1%) in individual human liver microsomes from 12 adult donors were highly variable, where an inverse association (R = −.784, p = .003) between UGT1A6 contribution and UGT1A9 probe substrate activity (ie, mycophenolic acid) was evident. Our novel findings provide valuable tools for conducting further mechanistic studies and for designing clinical interventions to mitigate the toxicities associated with p-cresol glucuronide. |
|---|---|
| AbstractList | Abstract
p-Cresol is a uremic toxin that is formed by intestinal microbiota and extensively conjugated by first-pass metabolism. p-Cresol glucuronide exerts various forms of cellular toxicity in vitro and is accumulated in the plasma of subjects with kidney disease, where associations with adverse cardiovascular and renal outcomes are evident. The objective of this study was to determine the contributions of human UDP-glucuronosyltransferase (UGT) enzymes in the formation of p-cresol glucuronide. Utilizing commonly expressed hepatic or renal human recombinant UGTs (ie, hrUGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, and 2B17), hrUGT1A6 and hrUGT1A9 exhibited the highest catalytic activities in the generation of p-cresol glucuronide. The kinetics of p-cresol glucuronide formation in hrUGT1A6 and pooled human liver microsomes were best described by the Hill equation and in hrUGT1A9 and pooled human kidney microsomes by substrate inhibition. Using inhibitory and selective UGT inhibitors (ie, acetaminophen or amentoflavone for UGT1A6 and niflumic acid for UGT1A9), UGT1A6 was identified the predominant enzyme responsible for p-cresol glucuronide production in pooled human liver (78.4%–81.3% contribution) and kidney (54.3%–62.9%) microsomes, whereas UGT1A9 provided minor contributions (2.8% and 35.5%, respectively). The relative contributions of UGT1A6 (72.6 ± 11.3%, mean ± SD) and UGT1A9 (5.7 ± 4.1%) in individual human liver microsomes from 12 adult donors were highly variable, where an inverse association (R = −.784, p = .003) between UGT1A6 contribution and UGT1A9 probe substrate activity (ie, mycophenolic acid) was evident. Our novel findings provide valuable tools for conducting further mechanistic studies and for designing clinical interventions to mitigate the toxicities associated with p-cresol glucuronide. p-Cresol is a uremic toxin that is formed by intestinal microbiota and extensively conjugated by first-pass metabolism. p-Cresol glucuronide exerts various forms of cellular toxicity in vitro and is accumulated in the plasma of subjects with kidney disease, where associations with adverse cardiovascular and renal outcomes are evident. The objective of this study was to determine the contributions of human UDP-glucuronosyltransferase (UGT) enzymes in the formation of p-cresol glucuronide. Utilizing commonly expressed hepatic or renal human recombinant UGTs (ie, hrUGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, and 2B17), hrUGT1A6 and hrUGT1A9 exhibited the highest catalytic activities in the generation of p-cresol glucuronide. The kinetics of p-cresol glucuronide formation in hrUGT1A6 and pooled human liver microsomes were best described by the Hill equation and in hrUGT1A9 and pooled human kidney microsomes by substrate inhibition. Using inhibitory and selective UGT inhibitors (ie, acetaminophen or amentoflavone for UGT1A6 and niflumic acid for UGT1A9), UGT1A6 was identified the predominant enzyme responsible for p-cresol glucuronide production in pooled human liver (78.4%-81.3% contribution) and kidney (54.3%-62.9%) microsomes, whereas UGT1A9 provided minor contributions (2.8% and 35.5%, respectively). The relative contributions of UGT1A6 (72.6 ± 11.3%, mean ± SD) and UGT1A9 (5.7 ± 4.1%) in individual human liver microsomes from 12 adult donors were highly variable, where an inverse association (R = -.784, p = .003) between UGT1A6 contribution and UGT1A9 probe substrate activity (ie, mycophenolic acid) was evident. Our novel findings provide valuable tools for conducting further mechanistic studies and for designing clinical interventions to mitigate the toxicities associated with p-cresol glucuronide. p-Cresol is a uremic toxin that is formed by intestinal microbiota and extensively conjugated by first-pass metabolism. p-Cresol glucuronide exerts various forms of cellular toxicity in vitro and is accumulated in the plasma of subjects with kidney disease, where associations with adverse cardiovascular and renal outcomes are evident. The objective of this study was to determine the contributions of human UDP-glucuronosyltransferase (UGT) enzymes in the formation of p-cresol glucuronide. Utilizing commonly expressed hepatic or renal human recombinant UGTs (ie, hrUGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, and 2B17), hrUGT1A6 and hrUGT1A9 exhibited the highest catalytic activities in the generation of p-cresol glucuronide. The kinetics of p-cresol glucuronide formation in hrUGT1A6 and pooled human liver microsomes were best described by the Hill equation and in hrUGT1A9 and pooled human kidney microsomes by substrate inhibition. Using inhibitory and selective UGT inhibitors (ie, acetaminophen or amentoflavone for UGT1A6 and niflumic acid for UGT1A9), UGT1A6 was identified the predominant enzyme responsible for p-cresol glucuronide production in pooled human liver (78.4%-81.3% contribution) and kidney (54.3%-62.9%) microsomes, whereas UGT1A9 provided minor contributions (2.8% and 35.5%, respectively). The relative contributions of UGT1A6 (72.6 ± 11.3%, mean ± SD) and UGT1A9 (5.7 ± 4.1%) in individual human liver microsomes from 12 adult donors were highly variable, where an inverse association (R = -.784, p = .003) between UGT1A6 contribution and UGT1A9 probe substrate activity (ie, mycophenolic acid) was evident. Our novel findings provide valuable tools for conducting further mechanistic studies and for designing clinical interventions to mitigate the toxicities associated with p-cresol glucuronide.p-Cresol is a uremic toxin that is formed by intestinal microbiota and extensively conjugated by first-pass metabolism. p-Cresol glucuronide exerts various forms of cellular toxicity in vitro and is accumulated in the plasma of subjects with kidney disease, where associations with adverse cardiovascular and renal outcomes are evident. The objective of this study was to determine the contributions of human UDP-glucuronosyltransferase (UGT) enzymes in the formation of p-cresol glucuronide. Utilizing commonly expressed hepatic or renal human recombinant UGTs (ie, hrUGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, and 2B17), hrUGT1A6 and hrUGT1A9 exhibited the highest catalytic activities in the generation of p-cresol glucuronide. The kinetics of p-cresol glucuronide formation in hrUGT1A6 and pooled human liver microsomes were best described by the Hill equation and in hrUGT1A9 and pooled human kidney microsomes by substrate inhibition. Using inhibitory and selective UGT inhibitors (ie, acetaminophen or amentoflavone for UGT1A6 and niflumic acid for UGT1A9), UGT1A6 was identified the predominant enzyme responsible for p-cresol glucuronide production in pooled human liver (78.4%-81.3% contribution) and kidney (54.3%-62.9%) microsomes, whereas UGT1A9 provided minor contributions (2.8% and 35.5%, respectively). The relative contributions of UGT1A6 (72.6 ± 11.3%, mean ± SD) and UGT1A9 (5.7 ± 4.1%) in individual human liver microsomes from 12 adult donors were highly variable, where an inverse association (R = -.784, p = .003) between UGT1A6 contribution and UGT1A9 probe substrate activity (ie, mycophenolic acid) was evident. Our novel findings provide valuable tools for conducting further mechanistic studies and for designing clinical interventions to mitigate the toxicities associated with p-cresol glucuronide. p-Cresol is a uremic toxin that is formed by intestinal microbiota and extensively conjugated by first-pass metabolism. p-Cresol glucuronide exerts various forms of cellular toxicity in vitro and is accumulated in the plasma of subjects with kidney disease, where associations with adverse cardiovascular and renal outcomes are evident. The objective of this study was to determine the contributions of human UDP-glucuronosyltransferase (UGT) enzymes in the formation of p-cresol glucuronide. Utilizing commonly expressed hepatic or renal human recombinant UGTs (ie, hrUGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, and 2B17), hrUGT1A6 and hrUGT1A9 exhibited the highest catalytic activities in the generation of p-cresol glucuronide. The kinetics of p-cresol glucuronide formation in hrUGT1A6 and pooled human liver microsomes were best described by the Hill equation and in hrUGT1A9 and pooled human kidney microsomes by substrate inhibition. Using inhibitory and selective UGT inhibitors (ie, acetaminophen or amentoflavone for UGT1A6 and niflumic acid for UGT1A9), UGT1A6 was identified the predominant enzyme responsible for p-cresol glucuronide production in pooled human liver (78.4%–81.3% contribution) and kidney (54.3%–62.9%) microsomes, whereas UGT1A9 provided minor contributions (2.8% and 35.5%, respectively). The relative contributions of UGT1A6 (72.6 ± 11.3%, mean ± SD) and UGT1A9 (5.7 ± 4.1%) in individual human liver microsomes from 12 adult donors were highly variable, where an inverse association (R = −.784, p = .003) between UGT1A6 contribution and UGT1A9 probe substrate activity (ie, mycophenolic acid) was evident. Our novel findings provide valuable tools for conducting further mechanistic studies and for designing clinical interventions to mitigate the toxicities associated with p-cresol glucuronide. |
| Author | Kiang, Tony K L Rong, Yan |
| Author_xml | – sequence: 1 givenname: Yan orcidid: 0000-0002-5252-6958 surname: Rong fullname: Rong, Yan organization: Faculty of Pharmacy and Pharmaceutical Sciences, Katz Group Centre for Pharmacy and Health Research, University of Alberta, Edmonton, Alberta T6G 2E1, Canada – sequence: 2 givenname: Tony K L surname: Kiang fullname: Kiang, Tony K L email: tkiang@ualberta.ca organization: Faculty of Pharmacy and Pharmaceutical Sciences, Katz Group Centre for Pharmacy and Health Research, University of Alberta, Edmonton, Alberta T6G 2E1, Canada |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32421801$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkM9LwzAYhoMo6qZXj9KjHjqTNP2Ro9S5CQM9uKOELP3iOttkJi24_fV267wI4ikf4XleeN8BOjbWAEJXBI8I5tFdY7-8Ku8-tJQ4pUfovPtNQswpPz7cCc7wGRp4v8KYkATzU3QWUUZJhsk5esuX0knVgCu3simt8YHVwbStpQnmDy_hpGpV66yxflM1ThqvwUkPwdhsNzX4oDRBs4Qgt2bVvu8Ddv46zB14W12gEy0rD5eHd4jmj-PXfBrOnidP-f0sVBHlTZhFiqacyUJrveBpxlkU6wJAQRqxuOAkiRlJY7rIdFpAEmMWc81VV4FSTHkWDdFNn7t29rMF34i69AqqShqwrReUYZZEPCWkQ68PaLuooRBrV9bSbcTPJB3AekA5670DLVTZ7Jt1_ctKECx2y4t-eXFYvtNGv7Sf5D-F216w7fo_9hv6l5ej |
| CitedBy_id | crossref_primary_10_1080_21688370_2022_2073175 crossref_primary_10_3390_toxins13070450 crossref_primary_10_1007_s40261_022_01121_1 crossref_primary_10_1080_03601234_2022_2116897 crossref_primary_10_3390_pharmaceutics13060857 crossref_primary_10_1080_03601234_2024_2384717 crossref_primary_10_1016_j_canlet_2025_217537 crossref_primary_10_1016_j_taap_2021_115553 crossref_primary_10_1016_j_pharmthera_2020_107689 crossref_primary_10_1002_mds_29959 crossref_primary_10_1016_j_ecoenv_2024_116281 crossref_primary_10_1007_s12161_024_02687_6 crossref_primary_10_1007_s00726_021_03064_x crossref_primary_10_1080_17425255_2024_2409257 crossref_primary_10_1080_19490976_2024_2431651 crossref_primary_10_3390_toxins15020116 |
| Cites_doi | 10.1021/pr4004213 10.1007/s00216-012-6277-z 10.3390/toxins10120520 10.1006/bbrc.1998.8908 10.1124/dmd.110.037036 10.1146/annurev.pharmtox.40.1.581 10.1074/jbc.M807961200 10.1016/j.transproceed.2011.11.023 10.1016/j.cbi.2018.02.009 10.1080/17512433.2018.1378095 10.1002/cpt.757 10.1371/journal.pone.0067168 10.1016/S0076-6879(02)57684-9 10.1124/dmd.114.062877 10.1124/mol.110.069336 10.1093/toxsci/kfz231 10.1016/j.bbadis.2012.09.006 10.1016/j.tiv.2015.07.020 10.1042/CS20160393 10.3390/toxins10010033 10.1124/dmd.118.084301 10.1124/dmd.108.023598 10.1016/j.tiv.2019.01.003 10.1016/S0009-8981(98)00124-7 10.1016/j.biocel.2013.02.019 10.1111/bcp.12889 10.1124/dmd.108.021105 10.3390/toxins9020052 10.1016/j.transproceed.2015.02.033 10.1016/j.pharmthera.2013.09.002 10.1073/pnas.85.22.8381 10.1093/ndt/14.12.2813 10.1002/jcph.1493 10.3109/03602530903210716 10.2152/jmi.66.81 10.1093/ndt/gfq818 10.1124/mol.114.093823 10.1016/j.pharmthera.2004.10.013 10.1124/dmd.113.053801 10.1124/dmd.32.4.413 10.1038/ki.2011.504 10.1093/ndt/gfr672 10.1007/s00216-012-5929-3 10.1124/dmd.111.043117 10.1080/07315724.2017.1334602 10.2215/CJN.00160116 10.2133/dmpk.22.152 10.1093/ndt/gfr056 10.1007/s00228-014-1709-7 10.1124/dmd.104.001651 10.1093/ndt/gfw009 10.1124/dmd.112.049171 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author(s) 2020. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020 – notice: The Author(s) 2020. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1093/toxsci/kfaa072 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1096-0929 |
| EndPage | 296 |
| ExternalDocumentID | 32421801 10_1093_toxsci_kfaa072 10.1093/toxsci/kfaa072 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -E4 .2P .I3 .ZR 0R~ 123 18M 1TH 1~5 29Q 2WC 4.4 48X 4G. 53G 5RE 5VS 5WA 5WD 7-5 70D A8Z AABZA AACTN AACZT AAHBH AAIMJ AAJKP AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP AAVLN ABEUO ABIXL ABJNI ABKDP ABMNT ABNHQ ABNKS ABPTD ABQLI ABWST ABXVV ABZBJ ACGFO ACGFS ACUFI ACUTJ ACUTO ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZTZ ADZXQ AEGPL AEGXH AEJOX AEKSI AELWJ AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFGWE AFIYH AFOFC AFXEN AGINJ AGKEF AGQXC AGSYK AHXPO AIJHB AJEEA AKHUL AKRWK AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ARIXL ATGXG AXUDD AYOIW BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BSWAC BTRTY BVRKM CDBKE CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EDH EE~ EMOBN ESTFP F5P F9B FDB FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HH5 HW0 HZ~ I-F IOX J21 KAQDR KBUDW KOP KQ8 KSI KSN M-Z M49 N9A NGC NLBLG NOMLY NOYVH NQ- NU- O-L O9- OAWHX OBOKY OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OWPYF P2P PAFKI PEELM Q1. Q5Y R44 RD5 ROL ROX RUSNO RW1 RXO SV3 TJX TLC TR2 W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~02 ~91 AAYWO AAYXX ABDFA ABEJV ABGNP ABPQP ABVGC ABXZS ADNBA AGORE AHGBF AHMMS AJBYB AJNCP ALXQX CITATION JXSIZ NPM 7X8 |
| ID | FETCH-LOGICAL-c329t-83c2794adfffb9789435fdeece7345d916541752b8f7de650459f9c2182202983 |
| ISSN | 1096-6080 1096-0929 |
| IngestDate | Fri Jul 11 09:08:24 EDT 2025 Thu Apr 03 06:54:16 EDT 2025 Thu Apr 24 23:05:33 EDT 2025 Tue Jul 01 02:41:33 EDT 2025 Wed Aug 28 03:18:37 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | human liver microsomes biotransformation human UDP-glucuronosyltransferases cresol glucuronide human kidney microsomes p-cresol glucuronide |
| Language | English |
| License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model The Author(s) 2020. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c329t-83c2794adfffb9789435fdeece7345d916541752b8f7de650459f9c2182202983 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-5252-6958 |
| PMID | 32421801 |
| PQID | 2404639711 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2404639711 pubmed_primary_32421801 crossref_citationtrail_10_1093_toxsci_kfaa072 crossref_primary_10_1093_toxsci_kfaa072 oup_primary_10_1093_toxsci_kfaa072 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20200801 2020-08-01 |
| PublicationDateYYYYMMDD | 2020-08-01 |
| PublicationDate_xml | – month: 08 year: 2020 text: 20200801 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Toxicological sciences |
| PublicationTitleAlternate | Toxicol Sci |
| PublicationYear | 2020 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | Walsky (2020081005564533500_kfaa072-B56) 2012; 40 Shou (2020081005564533500_kfaa072-B48) 2002; 357 Rowland (2020081005564533500_kfaa072-B46) 2008; 36 Liabeuf (2020081005564533500_kfaa072-B23) 2013; 8 Mackenzie (2020081005564533500_kfaa072-B29) 2008; 283 Miners (2020081005564533500_kfaa072-B35) 2011; 39 Harding (2020081005564533500_kfaa072-B15) 1988; 85 Vanholder (2020081005564533500_kfaa072-B54) 1999; 14 Liabeuf (2020081005564533500_kfaa072-B24) 2016; 130 Vanholder (2020081005564533500_kfaa072-B53) 2011; 26 Meijers (2020081005564533500_kfaa072-B33) 2011; 26 Gryp (2020081005564533500_kfaa072-B13) 2017; 9 Prokopienko (2020081005564533500_kfaa072-B44) 2018; 11 Meert (2020081005564533500_kfaa072-B32) 2012; 27 Huang (2020081005564533500_kfaa072-B17) 2012; 44 Rowland (2020081005564533500_kfaa072-B47) 2013; 45 Fallon (2020081005564533500_kfaa072-B11) 2013; 12 Meyer (2020081005564533500_kfaa072-B34) 2012; 81 (2020081005564533500_kfaa072-B52) 2018 Li (2020081005564533500_kfaa072-B22) 2007; 22 Lv (2020081005564533500_kfaa072-B27) 2018; 284 Stingl (2020081005564533500_kfaa072-B49) 2014; 141 Uchaipichat (2020081005564533500_kfaa072-B51) 2004; 32 Barnes (2020081005564533500_kfaa072-B3) 2014; 70 Badee (2020081005564533500_kfaa072-B1) 2019; 59 Itoh (2020081005564533500_kfaa072-B19) 2012; 403 Badee (2020081005564533500_kfaa072-B2) 2019; 47 Poesen (2020081005564533500_kfaa072-B43) 2016; 11 Rong (2020081005564533500_kfaa072-B45) 2020; 173 Weigand (2020081005564533500_kfaa072-B57) 2019; 56 Mutsaers (2020081005564533500_kfaa072-B38) 2015; 29 Ikematsu (2020081005564533500_kfaa072-B18) 2019; 66 Liu (2020081005564533500_kfaa072-B26) 2019 (2020081005564533500_kfaa072-B7) 2017 Houston (2020081005564533500_kfaa072-B16) 2000; 28 Beaulieu (2020081005564533500_kfaa072-B4) 1998; 248 Poesen (2020081005564533500_kfaa072-B42) 2016; 31 Knights (2020081005564533500_kfaa072-B21) 2016; 81 De Smet (2020081005564533500_kfaa072-B9) 1998; 278 Vanholder (2020081005564533500_kfaa072-B55) 2018; 10 Fallon (2020081005564533500_kfaa072-B10) 2013; 41 Margaillan (2020081005564533500_kfaa072-B30) 2015; 43 Bushey (2020081005564533500_kfaa072-B5) 2013; 41 Kiang (2020081005564533500_kfaa072-B20) 2005; 106 Guida (2020081005564533500_kfaa072-B14) 2017; 36 Fisher (2020081005564533500_kfaa072-B12) 2000; 28 Meech (2020081005564533500_kfaa072-B31) 2015; 87 Tukey (2020081005564533500_kfaa072-B50) 2000; 40 Ligabue (2020081005564533500_kfaa072-B25) 2015; 47 Mackenzie (2020081005564533500_kfaa072-B28) 2011; 79 Picard (2020081005564533500_kfaa072-B41) 2005; 33 Miners (2020081005564533500_kfaa072-B36) 2010; 42 Miners (2020081005564533500_kfaa072-B37) 2017; 102 Ohno (2020081005564533500_kfaa072-B40) 2009; 37 Cuoghi (2020081005564533500_kfaa072-B8) 2012; 404 Mutsaers (2020081005564533500_kfaa072-B39) 2013; 1832 Chinnappa (2020081005564533500_kfaa072-B6) 2018; 10 |
| References_xml | – volume: 12 start-page: 4402 year: 2013 ident: 2020081005564533500_kfaa072-B11 article-title: Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring publication-title: J. Proteome Res doi: 10.1021/pr4004213 – volume: 404 start-page: 2097 year: 2012 ident: 2020081005564533500_kfaa072-B8 article-title: Quantification of p-cresol sulphate in human plasma by selected reaction monitoring publication-title: Anal. Bioanal. Chem doi: 10.1007/s00216-012-6277-z – volume: 10 start-page: 520 year: 2018 ident: 2020081005564533500_kfaa072-B6 article-title: Association between protein-bound uremic toxins and asymptomatic cardiac dysfunction in patients with chronic kidney disease publication-title: Toxins (Basel) doi: 10.3390/toxins10120520 – volume: 248 start-page: 44 year: 1998 ident: 2020081005564533500_kfaa072-B4 article-title: Isolation and characterization of a human orphan UDP-glucuronosyltransferase, UGT2B11 publication-title: Biochem. Biophys. Res. Commun doi: 10.1006/bbrc.1998.8908 – year: 2018 ident: 2020081005564533500_kfaa072-B52 – volume: 39 start-page: 644 year: 2011 ident: 2020081005564533500_kfaa072-B35 article-title: Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: Application to the reaction phenotyping of acetaminophen glucuronidation publication-title: Drug Metab. Dispos doi: 10.1124/dmd.110.037036 – volume: 40 start-page: 581 year: 2000 ident: 2020081005564533500_kfaa072-B50 article-title: Human UDP-glucuronosyltransferases: Metabolism, expression, and disease publication-title: Annu. Rev. Pharmacol. Toxicol doi: 10.1146/annurev.pharmtox.40.1.581 – volume: 28 start-page: 560 year: 2000 ident: 2020081005564533500_kfaa072-B12 article-title: In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin publication-title: Drug Metab. Dispos – volume: 283 start-page: 36205 year: 2008 ident: 2020081005564533500_kfaa072-B29 article-title: Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase publication-title: J. Biol. Chem doi: 10.1074/jbc.M807961200 – volume: 44 start-page: 621 year: 2012 ident: 2020081005564533500_kfaa072-B17 article-title: Serum total p-cresol and indoxyl sulfate correlated with stage of chronic kidney disease in renal transplant recipients publication-title: Transplant. Proc doi: 10.1016/j.transproceed.2011.11.023 – volume: 284 start-page: 48 year: 2018 ident: 2020081005564533500_kfaa072-B27 article-title: Amentoflavone is a potent broad-spectrum inhibitor of human UDP-glucuronosyltransferases publication-title: Chem. Biol. Interact doi: 10.1016/j.cbi.2018.02.009 – volume: 11 start-page: 71 year: 2018 ident: 2020081005564533500_kfaa072-B44 article-title: Microbiota-derived uremic retention solutes: Perpetrators of altered nonrenal drug clearance in kidney disease publication-title: Expert Rev. Clin. Pharmacol doi: 10.1080/17512433.2018.1378095 – volume: 102 start-page: 436 year: 2017 ident: 2020081005564533500_kfaa072-B37 article-title: The role of the kidney in drug elimination: Transport, metabolism, and the impact of kidney disease on drug clearance publication-title: Clin. Pharmacol. Ther doi: 10.1002/cpt.757 – volume: 8 start-page: e67168 year: 2013 ident: 2020081005564533500_kfaa072-B23 article-title: Does p-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins? publication-title: PLoS One doi: 10.1371/journal.pone.0067168 – volume: 357 start-page: 261 year: 2002 ident: 2020081005564533500_kfaa072-B48 article-title: Kinetic analysis for multiple substrate interaction at the active site of cytochrome P450 publication-title: Methods Enzymol doi: 10.1016/S0076-6879(02)57684-9 – volume: 43 start-page: 611 year: 2015 ident: 2020081005564533500_kfaa072-B30 article-title: Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: A comparison of normal and tumoral kidney tissues publication-title: Drug Metab. Dispos doi: 10.1124/dmd.114.062877 – volume: 79 start-page: 472 year: 2011 ident: 2020081005564533500_kfaa072-B28 article-title: The novel UDP glycosyltransferase 3A2: Cloning, catalytic properties, and tissue distribution publication-title: Mol. Pharmacol doi: 10.1124/mol.110.069336 – volume: 173 start-page: 267 year: 2020 ident: 2020081005564533500_kfaa072-B45 article-title: Mechanisms of metabolism interaction between p-cresol and mycophenolic acid publication-title: Toxicol. Sci doi: 10.1093/toxsci/kfz231 – volume: 1832 start-page: 142 year: 2013 ident: 2020081005564533500_kfaa072-B39 article-title: Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration publication-title: Biochim. Biophys. Acta doi: 10.1016/j.bbadis.2012.09.006 – volume: 29 start-page: 1868 year: 2015 ident: 2020081005564533500_kfaa072-B38 article-title: Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: Implications for chronic kidney disease pathophysiology publication-title: Toxicol. In Vitro doi: 10.1016/j.tiv.2015.07.020 – start-page: 722 year: 2019 ident: 2020081005564533500_kfaa072-B26 article-title: Coexpression of human hepatic uridine diphosphate glucuronosyltransferase proteins: Implications for ontogenetic mechanisms and isoform coregulation publication-title: J. Clin. Pharmacol – volume: 130 start-page: 2209 year: 2016 ident: 2020081005564533500_kfaa072-B24 article-title: Protein-bound toxins: Has the Cinderella of uraemic toxins turned into a princess? publication-title: Clin. Sci. (Lond.) doi: 10.1042/CS20160393 – volume: 10 start-page: 33 year: 2018 ident: 2020081005564533500_kfaa072-B55 article-title: Biochemical and clinical impact of organic uremic retention solutes: A comprehensive update publication-title: Toxins (Basel) doi: 10.3390/toxins10010033 – volume: 47 start-page: 124 year: 2019 ident: 2020081005564533500_kfaa072-B2 article-title: Optimization of experimental conditions of automated glucuronidation assays in human liver microsomes using a cocktail approach and ultra-high performance liquid chromatography-tandem mass spectrometry publication-title: Drug Metab. Dispos doi: 10.1124/dmd.118.084301 – volume: 37 start-page: 32 year: 2009 ident: 2020081005564533500_kfaa072-B40 article-title: Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction publication-title: Drug Metab. Dispos doi: 10.1124/dmd.108.023598 – volume: 56 start-page: 52 year: 2019 ident: 2020081005564533500_kfaa072-B57 article-title: Uremic solutes modulate hepatic bile acid handling and induce mitochondrial toxicity publication-title: Toxicol. In Vitro doi: 10.1016/j.tiv.2019.01.003 – volume: 278 start-page: 1 year: 1998 ident: 2020081005564533500_kfaa072-B9 article-title: A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure publication-title: Clin. Chim. Acta doi: 10.1016/S0009-8981(98)00124-7 – volume: 45 start-page: 1121 year: 2013 ident: 2020081005564533500_kfaa072-B47 article-title: The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification publication-title: Int. J. Biochem. Cell Biol doi: 10.1016/j.biocel.2013.02.019 – volume: 81 start-page: 1153 year: 2016 ident: 2020081005564533500_kfaa072-B21 article-title: Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance publication-title: Br. J. Clin. Pharmacol doi: 10.1111/bcp.12889 – volume: 36 start-page: 1056 year: 2008 ident: 2020081005564533500_kfaa072-B46 article-title: The “albumin effect” and drug glucuronidation: Bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities publication-title: Drug Metab. Dispos doi: 10.1124/dmd.108.021105 – volume: 9 start-page: 52 year: 2017 ident: 2020081005564533500_kfaa072-B13 article-title: p-Cresyl sulfate publication-title: Toxins (Basel) doi: 10.3390/toxins9020052 – volume: 47 start-page: 2121 year: 2015 ident: 2020081005564533500_kfaa072-B25 article-title: p-Cresol and cardiovascular risk in kidney transplant recipients publication-title: Transplant. Proc doi: 10.1016/j.transproceed.2015.02.033 – volume: 141 start-page: 92 year: 2014 ident: 2020081005564533500_kfaa072-B49 article-title: Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review publication-title: Pharmacol. Ther doi: 10.1016/j.pharmthera.2013.09.002 – volume: 85 start-page: 8381 year: 1988 ident: 2020081005564533500_kfaa072-B15 article-title: Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells publication-title: Proc. Natl. Acad. Sci. U.S.A doi: 10.1073/pnas.85.22.8381 – volume: 14 start-page: 2813 year: 1999 ident: 2020081005564533500_kfaa072-B54 article-title: p-Cresol: A toxin revealing many neglected but relevant aspects of uraemic toxicity publication-title: Nephrol. Dial. Transplant doi: 10.1093/ndt/14.12.2813 – year: 2017 ident: 2020081005564533500_kfaa072-B7 – volume: 59 start-page: S42 year: 2019 ident: 2020081005564533500_kfaa072-B1 article-title: Characterization of the ontogeny of hepatic UDP-glucuronosyltransferase enzymes based on glucuronidation activity measured in human liver microsomes publication-title: J. Clin. Pharmacol doi: 10.1002/jcph.1493 – volume: 42 start-page: 196 year: 2010 ident: 2020081005564533500_kfaa072-B36 article-title: The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential publication-title: Drug Metab. Rev doi: 10.3109/03602530903210716 – volume: 66 start-page: 81 year: 2019 ident: 2020081005564533500_kfaa072-B18 article-title: Organ distribution of endogenous p-cresol in hemodialysis patients publication-title: J. Med. Invest doi: 10.2152/jmi.66.81 – volume: 26 start-page: 759 year: 2011 ident: 2020081005564533500_kfaa072-B33 article-title: The gut-kidney axis: Indoxyl sulfate, p-cresyl sulfate and CKD progression publication-title: Nephrol. Dial. Transplant doi: 10.1093/ndt/gfq818 – volume: 87 start-page: 442 year: 2015 ident: 2020081005564533500_kfaa072-B31 article-title: A novel function for UDP glycosyltransferase 8: Galactosidation of bile acids publication-title: Mol. Pharmacol doi: 10.1124/mol.114.093823 – volume: 106 start-page: 97 year: 2005 ident: 2020081005564533500_kfaa072-B20 article-title: UDP-glucuronosyltransferases and clinical drug-drug interactions publication-title: Pharmacol. Ther doi: 10.1016/j.pharmthera.2004.10.013 – volume: 41 start-page: 2076 year: 2013 ident: 2020081005564533500_kfaa072-B10 article-title: Targeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyl transferase 1A and 2B isoforms using nano-ultra-high-performance liquid chromatography/tandem mass spectrometry with selected reaction monitoring publication-title: Drug Metab. Dispos doi: 10.1124/dmd.113.053801 – volume: 32 start-page: 413 year: 2004 ident: 2020081005564533500_kfaa072-B51 article-title: Human UDP-glucuronosyltransferases: Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid publication-title: Drug Metab. Dispos doi: 10.1124/dmd.32.4.413 – volume: 28 start-page: 246 year: 2000 ident: 2020081005564533500_kfaa072-B16 article-title: In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model publication-title: Drug Metab. Dispos – volume: 81 start-page: 949 year: 2012 ident: 2020081005564533500_kfaa072-B34 article-title: Uremic solutes from colon microbes publication-title: Kidney Int doi: 10.1038/ki.2011.504 – volume: 27 start-page: 2388 year: 2012 ident: 2020081005564533500_kfaa072-B32 article-title: Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: Clinical data and pathophysiological implications publication-title: Nephrol. Dial. Transplant doi: 10.1093/ndt/gfr672 – volume: 403 start-page: 1841 year: 2012 ident: 2020081005564533500_kfaa072-B19 article-title: Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production publication-title: Anal. Bioanal. Chem doi: 10.1007/s00216-012-5929-3 – volume: 40 start-page: 1051 year: 2012 ident: 2020081005564533500_kfaa072-B56 article-title: Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: Altered alamethicin concentration and utility to screen for UGT inhibitors publication-title: Drug Metab. Dispos doi: 10.1124/dmd.111.043117 – volume: 36 start-page: 586 year: 2017 ident: 2020081005564533500_kfaa072-B14 article-title: Effect of a short-course treatment with synbiotics on plasma p-cresol concentration in kidney transplant recipients publication-title: J. Am. Coll. Nutr doi: 10.1080/07315724.2017.1334602 – volume: 11 start-page: 1136 year: 2016 ident: 2020081005564533500_kfaa072-B43 article-title: Metabolism, protein binding, and renal clearance of microbiota-derived p-cresol in patients with CKD publication-title: Clin. J. Am. Soc. Nephrol doi: 10.2215/CJN.00160116 – volume: 22 start-page: 152 year: 2007 ident: 2020081005564533500_kfaa072-B22 article-title: Human UGT1A8 and UGT1A10 mRNA are expressed in primary human hepatocytes publication-title: Drug Metab. Pharmacokinet doi: 10.2133/dmpk.22.152 – volume: 26 start-page: 1464 year: 2011 ident: 2020081005564533500_kfaa072-B53 article-title: Warning: The unfortunate end of p-cresol as a uraemic toxin publication-title: Nephrol. Dial. Transplant doi: 10.1093/ndt/gfr056 – volume: 70 start-page: 1097 year: 2014 ident: 2020081005564533500_kfaa072-B3 article-title: Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins publication-title: Eur. J. Clin. Pharmacol doi: 10.1007/s00228-014-1709-7 – volume: 33 start-page: 139 year: 2005 ident: 2020081005564533500_kfaa072-B41 article-title: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism publication-title: Drug Metab. Dispos doi: 10.1124/dmd.104.001651 – volume: 31 start-page: 1721 year: 2016 ident: 2020081005564533500_kfaa072-B42 article-title: The influence of renal transplantation on retained microbial-human co-metabolites publication-title: Nephrol. Dial. Transplant doi: 10.1093/ndt/gfw009 – volume: 41 start-page: 170 year: 2013 ident: 2020081005564533500_kfaa072-B5 article-title: Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism publication-title: Drug Metab. Dispos doi: 10.1124/dmd.112.049171 |
| SSID | ssj0011609 |
| Score | 2.4166937 |
| Snippet | Abstract
p-Cresol is a uremic toxin that is formed by intestinal microbiota and extensively conjugated by first-pass metabolism. p-Cresol glucuronide exerts... p-Cresol is a uremic toxin that is formed by intestinal microbiota and extensively conjugated by first-pass metabolism. p-Cresol glucuronide exerts various... |
| SourceID | proquest pubmed crossref oup |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 285 |
| Title | Characterizations of Human UDP-Glucuronosyltransferase Enzymes in the Conjugation of p-Cresol |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32421801 https://www.proquest.com/docview/2404639711 |
| Volume | 176 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgSNOkCUG5rNxkEBoPW1hiJ0v9iMqgAoH6kErjAUWJE6NBF1dtIi399RxfcqnKuL1EUeJclO_k-LN9zncQeukykY1SpaedpsLxg4w6zBWBE4Qkgf4UOr1UR_l-Pp3M_A_nwXlXmU5nl5Tpa77-ZV7J_6AKxwBXlSX7D8i2N4UDsA_4whYQhu1fYTxu1ZbXXUSbmZafvZ067-cVr5aykKt6XmqCmi-h0zo6K9b1pQ7E0rRzLIvv1beWOi6cMQzB5bxPWyN5dcFbN2l7zS5K3ob1fkl6S_p2HjqSRX300eY22NkF0sW2QedgPKKropSZnZZoXKap2WJtg_QdoCnAs-WYjWhVKa_gFWHnh0gS19Ts6eG0uNRAKY7njZq32BDDbk7dRLdIGHpa1nfSjnc879RlrTInPTGPO7EP20O7zeUbJGQjsXFrfKF5RnQH3bYDBPzGoH0X3ciLAdr9ZEMgBuhwasTG62Mcdblzq2N8iKedDHk9QPtmRhabRLN76OuWtWApsLYW_BtrwdZa8EWBwVpwz1rU9Y213Eezd2fReOLY4hoOp4SVzohyAr44yYQQKQuVDH8gsjzneUjhl2Uqyw2oJUlHIsxy4PF-wATjSvCfKNl--gDtFLLIDxAmbuZyTxDmidBPEpJQSrnHeEjzFPx7OkRO87VjbpXnVQGUeWwiIGhsgIotUEP0qm2_MJor17Z8AeD9sdHzBtsYfKdaEEuKXFarGNisrxa2PW-IHhrQ23s1pvLo2jOP0V73xzxBO-Wyyp8CQy3TZ9oqfwId45TE |
| linkProvider | ABC ChemistRy |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterizations+of+Human+UDP-Glucuronosyltransferase+Enzymes+in+the+Conjugation+of+p-Cresol&rft.jtitle=Toxicological+sciences&rft.au=Rong%2C+Yan&rft.au=Kiang%2C+Tony+K+L&rft.date=2020-08-01&rft.eissn=1096-0929&rft.volume=176&rft.issue=2&rft.spage=285&rft_id=info:doi/10.1093%2Ftoxsci%2Fkfaa072&rft_id=info%3Apmid%2F32421801&rft.externalDocID=32421801 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1096-6080&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1096-6080&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1096-6080&client=summon |